212. Tricuspid atresia
6 clinical trials,   8 drugs   (DrugBank: 7 drugs),   8 drug target genes,   12 drug target pathways

Searched query = "Tricuspid atresia", "TA"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04176458
(ClinicalTrials.gov)
April 21, 201912/2/2019Methacetin Breath Test in Patients With Liver Disease Secondary to Heart DiseaseNon-invasive Assessment of Liver Function in Patients Undergoing Heart and Liver Transplant EvaluationDilated Cardiomyopathy;Tricuspid AtresiaDevice: Methacetin Breath Test (MBT)Northwestern UniversityNULLRecruiting18 YearsN/AAll20N/AUnited States
2NCT01292551
(ClinicalTrials.gov)
February 20118/2/2011Study of Placebo or Bosentan to Treat Patients With Single Ventricle Physiology.Treatment With Endothelin Antagonist to Tcpc Patients; a Multicenter, Randomized, Prospective Study Measuring Maximal O2 Uptake in Ergometer Bicycle TestHypoplastic Left Heart Syndrome;Tricuspid Atresia;Other Specified Congenital Anomalies of HeartDrug: Bosentan;Drug: PlaceboRigshospitalet, DenmarkAarhus University Hospital;Bispebjerg Hospital;ActelionCompleted15 YearsN/ABoth75Phase 2Denmark;Sweden
3NCT00974025
(ClinicalTrials.gov)
June 20099/9/2009Impact of Vitamin C on Endothelial Function and Exercise Capacity in Fontan-Palliated PatientsVitamin C May Improve Endothelial Function and Exercise Capacity in Functional Single Ventricle Patients After Fontan PalliationFontan Procedure;Hypoplastic Left Heart Syndrome;Tricuspid AtresiaDietary Supplement: Vitamin C;Dietary Supplement: PlaceboUniversity of MichiganGriese-Hutchinson Champions for Children's Hearts Investigator AwardCompleted8 Years25 YearsAll53N/AUnited States
4NCT00507819
(ClinicalTrials.gov)
December 200725/7/2007Sildenafil After the Fontan OperationThe Sildenafil After Fontan Operation StudyHypoplastic Left Heart Syndrome;Tricuspid AtresiaDrug: Sildenafil;Drug: PlaceboChildren's Hospital of PhiladelphiaThe Mark H. and Blanche M. Harrington FoundationCompleted8 Years40 YearsAll28Phase 2United States
5NCT00573066
(ClinicalTrials.gov)
May 200411/12/2007Understanding Dexmedetomidine In Infants Post-Operative From Cardiac SurgeryThe Pharmacokinetics, Pharmacogenetics, and Pharmacodynamics of Dexmedetomidine In Infants Post-Operative From Cardiac SurgeryHypoplastic Left Heart;Tetralogy of Fallot;Tricuspid AtresiaDrug: DexmedetomidineAthena ZuppaNULLCompleted1 Month24 MonthsAll56Phase 1NULL
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT00004828
(ClinicalTrials.gov)
December 199424/2/2000Liothyronine in Children With Single Ventricle Congenital Cardiac Malformations Undergoing the Fontan ProcedureTricuspid Atresia;Heart Defects, CongenitalDrug: liothyronine I 131FDA Office of Orphan Products DevelopmentChildren's Hospital and Health CenterCompletedN/A17 YearsBoth28Phase 1NULL